Asthma Biologic Comparison: Nucala, Fasenra, Dupixent, Tezspire, and Xolair
Five FDA-approved biologics now target the underlying immune pathways that drive severe asthma. Each agent works differently, attaches to a distinct molecular target, and is most effective in patients with a specific biomarker profile. Choosing the right biologic is not guesswork — it is a data-driven decision based on blood eosinophil count, total IgE, fractional exhaled nitric oxide (FeNO), allergy status, and asthma phenotype.
This comparison guide covers all five agents side by side: omalizumab (Xolair), mepolizumab (Nucala), benralizumab (Fasenra), dupilumab (Dupixent), and tezepelumab (Tezspire). If you are a patient in the Plantation, Fort Lauderdale, or Broward County area seeking a biologic evaluation, please consult your physician or contact our clinic directly.
Five Biologics at a Glance
The table below summarizes the mechanism, molecular target, dosing schedule, and key eligibility criteria for each FDA-approved asthma biologic.
| Biologic (Brand) | Target | Mechanism | Dosing Schedule | Route | Key Eligibility Criteria |
|---|---|---|---|---|---|
| Omalizumab (Xolair) |
IgE | Anti-IgE monoclonal antibody; blocks free IgE from binding mast cells and basophils | Every 2 or 4 weeks (weight/IgE-based dosing table) | Subcutaneous | Age ≥6, moderate-severe allergic asthma, IgE 30–1500 IU/mL, positive allergen test to perennial aeroallergen |
| Mepolizumab (Nucala) |
IL-5 | Anti-IL-5 antibody; blocks IL-5 from binding eosinophil receptor, reducing eosinophil production and survival | Every 4 weeks (fixed 100 mg) | Subcutaneous | Age ≥6, severe eosinophilic asthma, blood eos ≥150 cells/μL at initiation or ≥300 in prior year |
| Benralizumab (Fasenra) |
IL-5Rα | Anti-IL-5 receptor antibody; ADCC mechanism depletes eosinophils directly (>90% reduction in 24 hours) | Q4W x3 loading doses, then Q8W maintenance | Subcutaneous | Age ≥12, severe eosinophilic asthma, blood eos ≥300 cells/μL at screening |
| Dupilumab (Dupixent) |
IL-4Rα | Blocks IL-4 and IL-13 signaling simultaneously; targets type 2 airway inflammation broadly | Q2W (400 mg loading then 200 mg; or 600 mg loading then 300 mg for OCS-dependent) | Subcutaneous | Age ≥12, moderate-severe uncontrolled asthma; blood eos ≥150 or FeNO ≥25 ppb; also OCS-dependent asthma and comorbid AD/CRSwNP |
| Tezepelumab (Tezspire) |
TSLP | Anti-TSLP antibody; blocks upstream epithelial alarmin initiating both type 2 and non-type 2 inflammation | Every 4 weeks (fixed 210 mg) | Subcutaneous | Age ≥12, severe uncontrolled asthma, no minimum eosinophil or IgE threshold -- broadest eligibility of all five biologics |
Biomarker-Based Selection Guide
Before prescribing a biologic, pulmonologists at Advanced Asthma Clinic order a targeted biomarker panel. These results determine which agent or agents are appropriate for each patient.
Blood Eosinophil Count
Eosinophils are the central biomarker for the anti-IL-5 agents (Nucala, Fasenra) and a supporting marker for dupilumab eligibility. A complete blood count with differential provides this number.
| Blood Eosinophils (cells/μL) | Interpretation | Biologic Options |
|---|---|---|
| <150 | Low eosinophilic burden | Tezepelumab (no threshold required); re-evaluate for non-type 2 phenotype |
| 150–299 | Borderline eosinophilia | Mepolizumab (if ≥150 at initiation or ≥300 in prior year), dupilumab, tezepelumab |
| ≥300 | Elevated eosinophilia | Benralizumab, mepolizumab, dupilumab, tezepelumab (all appropriate; selection by comorbidities and patient factors) |
Total IgE and Allergy Testing
Total IgE is the defining biomarker for omalizumab eligibility. Patients with moderate-to-severe allergic asthma, a positive skin prick test or RAST to a perennial allergen (dust mites, cockroach, mold, pet dander), and total IgE within the 30–1500 IU/mL range are candidates for omalizumab. In South Florida, perennial aeroallergen exposure is year-round given the humid subtropical climate — making allergic phenotype particularly relevant in Broward County practices.
FeNO (Fractional Exhaled Nitric Oxide)
FeNO measures airway eosinophilic inflammation non-invasively. A FeNO ≥25 ppb supports type 2 inflammation; ≥50 ppb strongly predicts steroid responsiveness and biologic eligibility. Read our detailed FeNO testing guide for full threshold tables and clinical interpretation.
| FeNO (ppb) | Significance | Biologic Relevance |
|---|---|---|
| <25 | Low type 2 inflammation | Consider tezepelumab; evaluate for non-eosinophilic phenotype or obesity-asthma overlap |
| 25–49 | Intermediate | Supports dupilumab (FeNO ≥25 is an eligibility criterion); also mepolizumab if blood eos ≥150 |
| ≥50 | High type 2 inflammation (IL-4/IL-13 driven) | Strong case for dupilumab; also supports mepolizumab, benralizumab, tezepelumab |
Each Biologic: Key Clinical Points
Omalizumab (Xolair) -- The Allergy Specialist
Omalizumab was the first biologic approved for asthma (2003) and remains the preferred agent for the allergic phenotype. It neutralizes free IgE before it can bind mast cells, dramatically reducing the allergic cascade triggered by aeroallergens. In Broward County's year-round allergy season, this is a clinically significant advantage for patients with sensitization to dust mites, cockroach, or outdoor molds.
Best fit: Patients with documented allergic sensitization, elevated IgE, and asthma that worsens with known allergen exposure. Consult your physician regarding eligibility.
Mepolizumab (Nucala) -- Precision Anti-Eosinophil
Mepolizumab blocks IL-5, the primary cytokine responsible for eosinophil growth, activation, and survival. The fixed 100 mg dose every four weeks and well-established long-term safety data (12+ years post-market) make it a reliable first-line choice for eosinophilic asthma. It is also approved for eosinophilic granulomatosis with polyangiitis (EGPA), which occasionally presents alongside severe asthma.
Best fit: Eosinophilic asthma with blood eos ≥150–300; especially when EGPA is a comorbidity.
Benralizumab (Fasenra) -- Rapid Deep Eosinophil Depletion
Rather than blocking IL-5 in circulation, benralizumab binds directly to the IL-5 receptor on eosinophils and triggers antibody-dependent cellular cytotoxicity (ADCC) — depleting over 90% of blood eosinophils within 24 hours of the first dose. The Q8W maintenance schedule (eight-week injection interval after three loading doses) is the least frequent dosing of any approved asthma biologic, which many patients find convenient.
Best fit: Eosinophilic asthma with blood eos ≥300; patients who prefer less frequent clinic visits during maintenance; oral corticosteroid-dependent disease with eosinophilia.
Dupilumab (Dupixent) -- Dual Pathway, Multiple Comorbidities
Dupilumab is unique in blocking both IL-4 and IL-13 signaling through a single receptor alpha-subunit (IL-4Rα). This dual blockade is particularly valuable for patients whose severe asthma is accompanied by atopic dermatitis, chronic rhinosinusitis with nasal polyps (CRSwNP), or eosinophilic esophagitis — all of which share the same type 2 inflammation pathway. For patients with oral corticosteroid (OCS)-dependent asthma, dupilumab has demonstrated significant OCS-sparing effects in clinical trials.
Best fit: Type 2 asthma with FeNO ≥25 and/or blood eos ≥150; OCS-dependent asthma; comorbid atopic dermatitis, CRSwNP, or eosinophilic esophagitis.
Tezepelumab (Tezspire) -- Broadest Eligibility
Tezepelumab targets thymic stromal lymphopoietin (TSLP), an epithelial-derived alarmin released in response to airway injury from allergens, viruses, pollution, and exercise. Because TSLP sits upstream of both type 2 and non-type 2 inflammation, tezepelumab is the only asthma biologic with no minimum eosinophil or IgE requirement. This makes it the agent of choice for patients with severe uncontrolled asthma who do not meet the biomarker thresholds for other biologics.
Best fit: Severe uncontrolled asthma regardless of biomarker profile; low-eosinophil severe asthma; patients who have failed or are ineligible for other biologics.
Clinical Decision Algorithm
The following stepwise algorithm reflects the approach used at Advanced Asthma Clinic for biologic selection. Individual patient factors — comorbidities, prior treatment history, dosing preference, insurance formulary — may modify the pathway. Always consult your physician before initiating or changing biologic therapy.
- Confirm eligibility: Patient must have severe asthma (Step 4–5 therapy) with ≥2 exacerbations in the prior year or chronic OCS dependence despite optimized inhaled therapy.
- Order biomarker panel: CBC with differential (blood eos), total IgE, allergen-specific IgE panel, FeNO (CPT 95012), weight and height.
- Allergic phenotype? If IgE 30–1500 with positive allergen test → Omalizumab is first consideration. If no, proceed.
- Blood eos ≥300? If yes → Benralizumab or mepolizumab (dupilumab/tezepelumab as alternatives).
- Blood eos 150–299 OR FeNO ≥25? If yes → Mepolizumab or dupilumab (dupilumab preferred if type 2 comorbidities present).
- OCS-dependent with type 2 markers? → Dupilumab or benralizumab (both have strong OCS-reduction trial data).
- No qualifying biomarker OR prior biologic failure? → Tezepelumab (no biomarker threshold required; broadest eligibility).
Insurance Coverage and Prior Authorization in Florida
All five FDA-approved asthma biologics are covered under Medicare Part B when administered in-office by a qualified provider. Florida Medicaid and most commercial payers — including Florida Blue, Aetna, Cigna, and UnitedHealthcare — cover these agents with prior authorization (PA).
What Prior Authorization Requires
- Documented severe asthma diagnosis (ICD-10: J45.50 or J45.51)
- Failure of optimized Step 4–5 inhaled therapy (high-dose ICS/LABA)
- Qualifying biomarker results specific to each agent
- Exacerbation history: typically ≥2 in the prior 12 months
- Step therapy requirements vary by payer and formulary tier
Advanced Asthma Clinic manages the PA process end-to-end and has a dedicated team for step therapy appeals. Patients should not delay treatment due to insurance uncertainty — contact our office at 954-522-7226 to begin the process.
Manufacturer Patient Assistance Programs
All five manufacturers offer co-pay assistance programs for commercially insured patients and patient assistance programs for uninsured or underinsured patients. Our team identifies the appropriate program at the time of PA submission.
Biologic Therapy at Advanced Asthma Clinic, Plantation FL
Advanced Asthma Clinic serves patients from Plantation, Fort Lauderdale, Coral Springs, Davie, Weston, Miramar, and throughout Broward County. Dr. Frank Hull brings more than 20 years of pulmonary research experience to biologic prescribing decisions — including active participation in clinical trials evaluating next-generation asthma therapies. Our office conducts FeNO testing (CPT 95012), spirometry, bronchoprovocation, and full allergy panels on-site, enabling same-visit biomarker evaluation and biologic planning.
Biologic injections are administered in our Plantation office under observation. Most injections take 15–30 minutes with a brief post-injection monitoring period. For patients participating in our Better Breathing Grant program, financial assistance may be available for costs associated with biologic initiation.
Schedule a Biologic Evaluation
Not sure which biologic is right for you? Our team will review your history, order appropriate biomarker testing, and develop a personalized treatment plan.
Call: 954-522-7226
Frequently Asked Questions
Which asthma biologic works best?
There is no single best biologic. The right choice depends on your biomarker profile -- blood eosinophil count, total IgE, FeNO, and allergy status. Tezepelumab (Tezspire) is the broadest-eligibility option with no minimum biomarker threshold. Xolair (omalizumab) targets allergic asthma specifically. Your pulmonologist will match the biologic to your individual phenotype. Always consult your physician before starting or changing any biologic therapy.
What blood tests determine biologic eligibility?
Key tests include: (1) complete blood count with differential for blood eosinophil count, (2) total IgE and allergen-specific IgE panel, (3) FeNO via CPT 95012, and (4) body weight for Xolair dosing. These biomarkers map to specific biologics and are covered by Medicare and commercial insurance when ordered in the context of severe uncontrolled asthma.
Can you switch from one biologic to another?
Yes. If a biologic does not reduce exacerbations or improve symptom control adequately after a 4–6 month trial, switching to a biologic with a different mechanism is appropriate. Research suggests that up to 30% of patients who respond inadequately to one anti-IL-5 agent may respond better to a different biologic pathway. Switching decisions are guided by updated biomarker testing and clinical response data.
How long does it take for asthma biologics to work?
Most patients notice exacerbation reduction within 3–4 months. Full clinical benefit — including quality-of-life improvement, reduced rescue inhaler use, and corticosteroid reduction — typically emerges over 6–12 months of consistent treatment.
Does insurance cover asthma biologics in Florida?
Yes. All five FDA-approved asthma biologics are covered by Medicare Part B (administered in office) and most Florida commercial plans. Prior authorization is required for all five agents. Advanced Asthma Clinic handles prior authorization and step therapy appeals on behalf of patients. Call 954-522-7226 to start the process.
Are biologics safe for long-term use?
Long-term safety data for these agents is reassuring. Omalizumab and mepolizumab have the longest post-market records (20+ and 10+ years respectively), with no concerning long-term safety signals identified. All five biologics continue to be monitored through pharmacovigilance programs. Consult your physician regarding individual risk factors and monitoring requirements.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual biologic eligibility, dosing, and prescribing decisions must be made by a qualified physician. Always consult your doctor before initiating, switching, or discontinuing biologic therapy. Information is accurate as of publication date and subject to change as new clinical data emerge.